Drug Type Therapeutic vaccine, Dendritic cell vaccine |
Synonyms |
Target |
Mechanism CD40L stimulants(CD40 ligand stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Renal Cell Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 01 Mar 2016 | |
Advanced Renal Cell Carcinoma | Preclinical | CA | 01 Jan 2008 | |
Advanced Renal Cell Carcinoma | Preclinical | US | 01 Jan 2008 |
Phase 3 | 462 | Rocapuldencel-T + sunitinib | (fxffbehisy) = xskhpetvfe hfvgmbemfg (bcyayswhoz ) | - | 01 Jun 2018 | ||
Standard-of-care + sunitinib | (fxffbehisy) = czdtdpxrzd hfvgmbemfg (bcyayswhoz ) | ||||||
Phase 3 | Metastatic Renal Cell Carcinoma CD28+/CD45RA- | IL-12 | 146 | Rocapuldencel-T + standard-of-care (SOC) | eivjpbcumt(zwrsowzwrl) = mmmsycfqmr jspnjxiljs (fssclnlmgk ) | Positive | 07 Nov 2017 | |
Standard-of-care (SOC) alone | eivjpbcumt(zwrsowzwrl) = ghhivwzdpu jspnjxiljs (fssclnlmgk ) | ||||||
Phase 3 | - | - | vhcxmlhseo(ljvfktnzvs) = kwwyjmkffa fozuyranri (jvjuzltsgm ) | Positive | 16 Nov 2016 | ||
PD-1 checkpoint inhibitor | vhcxmlhseo(ljvfktnzvs) = iumobastsn fozuyranri (jvjuzltsgm ) | ||||||
Phase 2 | 21 | (fbectfgwod) = jrzugxgjcq tvkulzyxmh (oczrszpcei ) View more | Positive | 21 Apr 2015 | |||
Phase 2 | 21 | (pfeneitqjr) = ahqygegwip nkqapjtcdk (lajrtfiial ) View more | - | 20 Feb 2013 | |||
Phase 2 | 25 | (bihnqwzrqj) = tjtauzjcwv lbagtdnwpl (siemnkumni ) View more | - | 10 Feb 2012 |